ALNYLAM PHARMACEUTICALS, INC.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $ALNY in the last 30 days.
See all $ALNY insider activity →Alnylam Pharmaceuticals (ALNY) stock fell 40% from its peak in 2026, but 22 of 29 analysts rate it 'buy' or 'strong buy' with a 50% upside. Revenue grew 72% YoY in Q2, and analysts see long-term potential despite guidance cuts. Pfizer's (PFE) patent and AstraZeneca's (AZN) setback may benefit Alnylam's pipeline.
Alnylam Pharmaceuticals (ALNY) stock rose 8.51% on positive RNAi pipeline updates and analyst upgrades. Analysts set price targets ranging from $318 to $455, citing strong clinical data and growth prospects. The company reported $3.71B in trailing revenue, a 92.1% gross margin, and positive EBIT margin of 23.4%.
Alnylam Pharmaceuticals (ALNY) rose 3.4% on September 2, 2026, driven by investor reaction to its late-August ESC Congress data update, which highlighted positive subgroup and pooled analyses for vutrisiran and zilebesiran. The company also announced upcoming investor conference webcasts. No major regulatory filings were tied to the gain.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning ALNY (ALNYLAM PHARMACEUTICALS, INC.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent ALNY coverage spans market movers, technology and financial news.
Analyst sentiment is positive, but no new catalyst is disclosed.
Upgrades and positive trial results reduce downside risk and suggest further upside.
Short-term price uptick driven by data recap and upcoming webcast, no new clinical or regulatory milestone.
Potential upside as investors may view Alnylam as a viable alternative in the ATTR‑CM space.
Analyst upgrade with higher target may support price gains.
AlphAI scores every news story that mentions ALNY with an AI model for sentiment and relevance, and aggregates insider trades from ALNYLAM PHARMACEUTICALS, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Alnylam Pharmaceuticals (ALNY) stock fell 40% from its peak in 2026, but 22 of 29 analysts rate it 'buy' or 'strong buy' with a 50% upside. Revenue grew 72% YoY in Q2, and analysts see long-term potential despite guidance cuts. Pfizer's (PFE) patent and AstraZeneca's (AZN) setback may benefit Alnylam's pipeline.
3 min readAlnylam Pharmaceuticals (ALNY) stock rose 8.51% on positive RNAi pipeline updates and analyst upgrades. Analysts set price targets ranging from $318 to $455, citing strong clinical data and growth prospects. The company reported $3.71B in trailing revenue, a 92.1% gross margin, and positive EBIT margin of 23.4%.
3 min readAlnylam Pharmaceuticals (ALNY) rose 3.4% on September 2, 2026, driven by investor reaction to its late-August ESC Congress data update, which highlighted positive subgroup and pooled analyses for vutrisiran and zilebesiran. The company also announced upcoming investor conference webcasts. No major regulatory filings were tied to the gain.
1 min readAstraZeneca (AZN) and Ionis Pharmaceuticals (IONS) discontinued a phase 3 trial for Wainua, a combination therapy for ATTR-CM. Analysts debate whether Alnylam Pharmaceuticals (ALNY) can succeed with its RNA silencing drugs in this area. ALNY's drugs are being considered for use with standard TTR stabilizers, targeting the disease through different pathways. The outcome may impact the ATTR-CM market and RNA therapeutics sector.
2 min readAnalysts at Jefferies, Evercore ISI, and BMO Capital maintained Buy ratings on Ascendis Pharma (ASND), Alnylam Pharma (ALNY), and Crispr Therapeutics (CRSP), with price targets of $330, $325.20, and $76 respectively. The consensus ratings are Strong Buy for ASND and ALNY, and Moderate Buy for CRSP, with average price targets indicating potential upside.
2 min readAlnylam Pharmaceuticals shared data supporting Amvuttra's use in various transthyretin amyloidosis patients, including those on Pfizer's tafamidis. The company also reported positive subgroup results for its experimental drug zilebesiran.
2 min readAlnylam Pharmaceuticals (ALNY) presented new data at ESC Congress 2026, showing consistent clinical benefits of vutrisiran across ATTR-CM patient populations and treatment settings. Additional analyses highlighted the potential of vutrisiran in addressing multisystemic manifestations of ATTR-CM and the consistent treatment effects of RNAi-powered TTR silencing across sexes. The company also presented data on zilebesiran, an investigational RNAi therapeutic for uncontrolled hypertension, showing
3 min readIonis (IONS) and AstraZeneca (AZN) presented full data from a failed trial of Wainua for transthyretin amyloid cardiomyopathy (ATTR-CM). Jefferies sees neutral to negative implications for Alnylam (ALNY), which is developing similar drugs. ALNY shares closed flat, IONS down 2%, and AZN down 1% on Friday. The trial missed its primary goal, raising doubts about ALNY's TTR business.
2 min readAlnylam Pharmaceuticals' stock fell 4.9% pre-market as negative data from a competitor's trial raised concerns about its RNA-silencing drug class. Wells Fargo cut its price target to $256. The company also faces competitive pressure and lowered its 2026 revenue guidance in July.
2 min readAlnylam Pharmaceuticals (ALNY) shares dropped 6% after AstraZeneca's Phase 3 trial for a silencer drug targeting ATTR-CM failed, showing no improvement in patients already on stabilizer drugs. The results raise concerns about silencer drugs in the competitive ATTR-CM treatment market, which is expected to be worth billions.
2 min read
